Management is delivering on its plan to expand into healthcare technology.
LATEST ARTICLES
The stock is down 25% since our pick but we aren’t willing to wave the white flag quite yet.
Expansion into high-tech audio, fire protection, and even medical devices has the company poised for growth that isn’t reflected in its stock price.
The stock can supply portfolios with their own long-term care.
The stock has room to rebound even further, and is a buy at these levels.
The company’s history of innovation, earnings trajectory, and growth drivers makes its stock a buy.
Earnings momentum, pricing power, and barriers to entry can help the alloy manufacturer’s stock advance 42% from here.
The stock can double from here as cost savings from AI and other strategic initiatives pay off.
The stock is up 66% since Barron’s Investor Circle picked it.
The stock can rally by 75% or more in the coming 12 months.
The stock is still packed with positive catalysts.
Sonoco Products trades at a compelling valuation, especially given its growth drivers and a safe dividend yield.
The war has already taken a toll on energy infrastructure. Cactus should be a big part of the rebuilding.
Harmony Biosciences is cheap, and could double in price from current levels.
Corpay’s stock is undervalued and not priced for enough growth.
An analysis shows that six members of the company’s management team and two board members have increased their holdings.
The company has learned its lessons. The stock stands to gain more than 30%.
The bull and bear case for Addus HomeCare stock.
The stock has moved little despite impressive financial results. Its expansion into private credit is one avenue to growth.
There are compelling reasons for investors to consider Robert Half stock, while underlying factors keep us from selecting it as a pick.
of 2 pages